Scarletred®Vision enables 3D Assessment and Monitoring in Epidermolysis Bullosa (EB) with ARORA®AI. Beyond the detection of blisters, Scarletred®Vision assesses their stage and precisely measures their area, depth and volume.

Ozempic® is a GLP-1 therapy known for rapid weight loss, but it can also cause facial changes often referred to as Ozempic® Face. Scarletred® Vision allows early detection and monitoring of these changes.

SCARLETRED is honored to be featured in the dermatology-focused professional journal DermaForum - published by mgo medizin. The scientific article was additionally published in a print run of 6.500 copies.

Speaking at AUTOMA+ 2025, SCARLETRED CEO Dr. Harald Schnidar shows how SCARLETRED®Vision, a CE-certified platform, transforms dermatology with remote, clinically validated, AI-powered skin assessments.

We are proud to share that SCARLETRED has been featured by ADVANTAGE AUSTRIA as one of Austria’s leading MedTech innovators, advancing AI-powered dermatology, standardized skin imaging, and remote skin assessment.

We are proud to announce that the results of our Phase I clinical trial, conducted amid the challenges of the COVID-19 pandemic, have been published in the peer-reviewed journal Clinical Pharmacokinetics.

At SCARLETRED, we observe that organizations adopt AI in distinct stages of maturity. We describe this evolution as the Three Waves of AI in Clinical Skin Imaging. Our framework helps to identify which AI wave you are on.